Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study

Wynton B Overcast; Jianying Zhang; Debra L Zynger; Gary H Tozbikian

doi:10.1007/s00428-016-1951-8

Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study

Virchows Arch. 2016 Aug;469(2):203-12. doi: 10.1007/s00428-016-1951-8. Epub 2016 May 25.

Authors

Wynton B Overcast¹, Jianying Zhang², Debra L Zynger³, Gary H Tozbikian⁴

Affiliations

¹ College of Medicine, Ohio State University, 410 W. 10th Ave, E410 Doan Hall, Columbus, OH, 43210, USA.
² Center of Biostatistics, Ohio State University, 320 Lincoln Tower, 1800 Cannon Drive, Columbus, OH, 43210, USA.
³ Department of Pathology, The Ohio State University Wexner Medical Center, 410 W. 10th Ave, E410 Doan Hall, Columbus, OH, 43210, USA.
⁴ Department of Pathology, The Ohio State University Wexner Medical Center, 410 W. 10th Ave, E410 Doan Hall, Columbus, OH, 43210, USA. Gary.Tozbikian@osumc.edu.

PMID: 27220765
DOI: 10.1007/s00428-016-1951-8

No abstract available

Keywords: ASCO/CAP guidelines; Breast cancer; Equivocal category; HER2 fluorescence in situ hybridization (FISH); HER2 immunohistochemistry (IHC).

MeSH terms

Adult
Aged
Biopsy*
Breast Neoplasms / diagnosis
Breast Neoplasms / metabolism*
Breast Neoplasms / pathology*
Female
Humans
Middle Aged
Neoplasm Invasiveness
Practice Guidelines as Topic*
Receptor, ErbB-2 / analysis
Receptor, ErbB-2 / metabolism*
Retrospective Studies

Substances

ERBB2 protein, human
Receptor, ErbB-2